Molecular disease presentation in diabetic nephropathy.

@article{Heinzel2015MolecularDP,
  title={Molecular disease presentation in diabetic nephropathy.},
  author={Andreas Heinzel and Irmgard M{\"u}hlberger and Gil Stelzer and Doron Lancet and Rainer Oberbauer and Mar{\'i}a Mart{\'i}n and Paul Perco},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2015},
  volume={30 Suppl 4},
  pages={
          iv17-25
        }
}
  • A. Heinzel, I. Mühlberger, P. Perco
  • Published 1 August 2015
  • Biology
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Diabetic nephropathy, as the most prevalent chronic disease of the kidney, has also become the primary cause of end-stage renal disease with the incidence of kidney disease in type 2 diabetics continuously rising. As with most chronic diseases, the pathophysiology is multifactorial with a number of deregulated molecular processes contributing to disease manifestation and progression. Current therapy mainly involves interfering in the renin-angiotensin-aldosterone system using angiotensin… 
Biomarkers of diabetic kidney disease
TLDR
The potential of high-dimensional panels of lipids, metabolites and proteins to advance the field is reviewed, and some of the analytical and post-analytical challenges of taking initial studies using these and candidate approaches through to actual clinical biomarker use are pointed to.
Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes
TLDR
A small set of serum protein biomarkers identified using a systems biology approach, combined with clinical variables, enhances the prediction of renal function loss over a wide range of baseline eGFR values in patients with type 2 diabetes and CKD.
The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease.
  • K. Cisek, M. Krochmal, J. Klein, H. Mischak
  • Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2016
TLDR
Key databases and bioinformatics tools are described and how systems biology and visualization tools can be used to generate clinically relevant molecular models with the capability to identify specific disease pathways, recognize key events in disease development and track disease progression are described.
The nephrologist of tomorrow: towards a kidney-omic future
TLDR
The current knowledge of different omics technologies in kidney diseases, specifically in the field of pediatric nephrology, is discussed, including biomarker discovery, defining as yet unrecognized biologic therapeutic targets and linking omics to relevant standard indices and clinical outcomes.
Management of Diabetes Mellitus
TLDR
The primary care physician is ideally placed to manage diabetes, both directly and via assembling and coordinating a multidisciplinary team with the common goal of improving the quantity and quality of life of their patient with diabetes.
Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes
TLDR
Twelve of the 17 candidate biomarkers were associated with eGFR decline, but their predictive power was low, and early interventions would likely be cost-effective.
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus
TLDR
A serum metabolite classifier was discovered and externally validated to significantly improve prediction of albuminuria response to ARBs in diabetes mellitus and specifically ADMA impacting eNOS activity appears to be a relevant factor in ARB response.
The effect of dicarbonyl stress on the development of kidney dysfunction in metabolic syndrome – a transcriptomic and proteomic approach
TLDR
The hypothesis that dicarbonyl stress plays a key role in renal microvascular complications is supported after an over-representation of genes related to oxidative stress and pro-inflammatory signalling pathways as well as an inhibition of angiogenesis suggesting its contribution to renal fibrosis.
...
...

References

SHOWING 1-10 OF 61 REFERENCES
Urinary MicroRNA Profiling in the Nephropathy of Type 1 Diabetes
TLDR
Urinary microRNA profiles differ across the different stages of diabetic nephropathy, and combining expression ratios of microRNAs with formal inferences about their predicted mRNA targets and associated biological pathways may yield useful markers for early diagnosis and risk stratification of DN in T1D by inferring the alteration of renal molecular processes.
Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy
TLDR
Urinary proteomics enables noninvasive assessment of DN risk at an early stage via determination of specific collagen fragments and thereby postponing/preventing the need for renal replacement therapy.
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.
TLDR
It is concluded that urine metabolomics is a reliable source for biomarkers of diabetic complications, and the data suggest that renal organic ion transport and mitochondrial function are dysregulated in diabetic kidney disease.
Gene networks implicated in diabetic kidney disease.
TLDR
It is found that dysregulation of cell proliferation may significantly contribute to the development of DKD, and DKD may be an immune-mediated degenerative disease.
Network-centric Analysis of Genetic Predisposition in Diabetic Nephropathy.
TLDR
This review extracts from the literature the most promising candidate genes thought to confer susceptibility to diabetic nephropathy and mapped them to affected pathways by using network-centric analysis.
Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study)
TLDR
The potential of multivariate data analysis and metabolomics in the field of diabetic complications, and suggests several metabolic pathways relevant for further biological studies, is demonstrated.
Pirfenidone is renoprotective in diabetic kidney disease.
TLDR
PFD is renoprotective in diabetic kidney disease and may exert its antifibrotic effects, in part, via inhibiting RNA processing, as identified in 21 proteins unique to PFD-treated diabetic kidneys.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
TLDR
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug.
Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy
TLDR
The identification of a specific NF-κB promoter module activated in the inflammatory stress response of progressive DN has helped to characterize upstream pathways as potential targets for the treatment of progressive renal diseases such as DN.
CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis
TLDR
Recently defined in a large population, CKD273 is the first proteomic-based classifier successfully tested for prognosis of CKD progression in an independent cohort and was different in the groups with different renal function.
...
...